 Receptors, Thrombin
"Receptors, Thrombin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of proteinase-activated receptors that are specific for THROMBIN. They are found primarily on PLATELETS and on ENDOTHELIAL CELLS. Activation of thrombin receptors occurs through the proteolytic action of THROMBIN, which cleaves the N-terminal peptide from the receptor to reveal a new N-terminal peptide that is a cryptic ligand for the receptor. The receptors signal through HETEROTRIMERIC GTP-BINDING PROTEINS. Small synthetic peptides that contain the unmasked N-terminal peptide sequence can also activate the receptor in the absence of proteolytic activity.
| Descriptor ID |
D018179
|
| MeSH Number(s) |
D12.776.395.550.625.800 D12.776.543.550.625.800 D12.776.543.750.695.875 D12.776.543.750.705.675.892 D12.776.543.750.750.850 D12.776.543.750.792.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Thrombin".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Glycoproteins [D12.776.395]
- Membrane Glycoproteins [D12.776.395.550]
- Platelet Membrane Glycoproteins [D12.776.395.550.625]
- Receptors, Thrombin [D12.776.395.550.625.800]
- Membrane Proteins [D12.776.543]
- Membrane Glycoproteins [D12.776.543.550]
- Platelet Membrane Glycoproteins [D12.776.543.550.625]
- Receptors, Thrombin [D12.776.543.550.625.800]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, G-Protein-Coupled [D12.776.543.750.695]
- Receptors, Thrombin [D12.776.543.750.695.875]
- Receptors, Immunologic [D12.776.543.750.705]
- Platelet Membrane Glycoproteins [D12.776.543.750.705.675]
- Receptors, Thrombin [D12.776.543.750.705.675.892]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Thrombin [D12.776.543.750.750.850]
- Receptors, Proteinase-Activated [D12.776.543.750.792]
- Receptors, Thrombin [D12.776.543.750.792.500]
Below are MeSH descriptors whose meaning is more specific than "Receptors, Thrombin".
This graph shows the total number of publications written about "Receptors, Thrombin" by people in this website by year, and whether "Receptors, Thrombin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 | | 2000 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2013 | 1 | 1 | 2 | | 2014 | 1 | 1 | 2 | | 2015 | 1 | 1 | 2 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Thrombin" by people in Profiles.
-
Denorme F, Armstrong ND, Stoller ML, Portier I, Tugolukova EA, Tanner RM, Montenont E, Bhatlekar S, Cody M, Rustad JL, Ajanel A, Tolley ND, Murray DC, Boyle JL, Nieman MT, McKenzie SE, Yost CC, Lange LA, Cushman M, Irvin MR, Bray PF, Campbell RA. The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes. J Clin Invest. 2023 09 15; 133(18).
-
Priestley ES, Banville J, Deon D, Dub? L, Gagnon M, Guy J, Lapointe P, Lavall?e JF, Martel A, Plamondon S, R?millard R, Ruediger E, Tremblay F, Posy SL, Guarino VR, Richter JM, Li J, Gupta A, Vetrichelvan M, Balapragalathan TJ, Mathur A, Hua J, Callejo M, Guay J, Sum CS, Cvijic ME, Watson C, Wong P, Yang J, Bouvier M, Gordon DA, Wexler RR, Marinier A. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4. J Med Chem. 2022 07 14; 65(13):8843-8854.
-
Aldrovandi M, Hinz C, Lauder SN, Podmore H, Hornshaw M, Slatter DA, Tyrrell VJ, Clark SR, Marnett LJ, Collins PW, Murphy RC, O'Donnell VB. DioxolaneA3-phosphatidylethanolamines are generated by human platelets and stimulate neutrophil integrin expression. Redox Biol. 2017 04; 11:663-672.
-
Bohula EA, Aylward PE, Bonaca MP, Corbalan RL, Kiss RG, Murphy SA, Scirica BM, White H, Braunwald E, Morrow DA. Efficacy and Safety of Vorapaxar With and Without a Thienopyridine for Secondary Prevention in Patients With Previous Myocardial Infarction and No History of Stroke or Transient Ischemic Attack: Results from TRA 2?P-TIMI 50. Circulation. 2015 Nov 17; 132(20):1871-9.
-
Cavender MA, Scirica BM, Bonaca MP, Angiolillo DJ, Dalby AJ, Dellborg M, Morais J, Murphy SA, Ophuis TO, Tendera M, Braunwald E, Morrow DA. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation. 2015 Mar 24; 131(12):1047-53.
-
Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, Goto S, Nilsen DW, Bonarjee V, Murphy SA, Morrow DA. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 ?P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 09; 64(22):2318-26.
-
Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, O'Donoghue ML, Murphy SA, Morrow DA. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2? P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 09; 64(22):2309-17.
-
Getz TM, Manne BK, Buitrago L, Mao Y, Kunapuli SP. Dextran sulphate induces fibrinogen receptor activation through a novel Syk-independent PI-3 kinase-mediated tyrosine kinase pathway in platelets. Thromb Haemost. 2013 Jun; 109(6):1131-40.
-
Boulaftali Y, Hess PR, Getz TM, Cholka A, Stolla M, Mackman N, Owens AP, Ware J, Kahn ML, Bergmeier W. Platelet ITAM signaling is critical for vascular integrity in inflammation. J Clin Invest. 2013 Feb; 123(2):908-16.
-
Bonaca MP, Morrow DA. SCH 530348: a novel oral thrombin receptor antagonist. Future Cardiol. 2009 Sep; 5(5):435-42.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|